Lumipulse G NfL Blood assay

Chemiluminescent immunoassay kit for detecting neurofilament protein biomarkers associated with Alzheimer's disease. Enables early diagnosis and disease monitoring in clinical laboratory settings. Provides quantitative measurement with high sensitivity and specificity for neurodegenerative disease assessment.

In vitro diagnostic assay kit for quantitative detection of Alzheimer-associated neurofilament protein using fluorometric chromatography. Enables early-stage diagnosis and monitoring of neurodegenerative disease progression in clinical laboratories. Provides rapid, sensitive biomarker measurement for cognitive impairment assessment.

Enzyme-linked immunoassay kit for detecting neurofilament proteins associated with Alzheimer's disease. Designed for early diagnosis and clinical assessment of neurodegenerative conditions in laboratory settings. The kit provides quantitative measurement of biomarkers indicative of neuronal damage and cognitive decline.

Chemiluminescence-based assay for detection of liver fibrosis biomarkers. Supports non-invasive assessment of hepatic fibrosis and liver disease progression. Multiple regulatory approvals across domestic and international markets.

Chemiluminescence immunoassay for quantitative measurement of inflammatory markers. Included in the company's extensive chemiluminescence product line of over 70 registered assays. Supports clinical inflammation assessment and monitoring.

Chemiluminescence immunoassay for anemia-related biomarkers and hematological parameters. Registered diagnostic test product supporting anemias diagnosis and evaluation. Included in the company's broad chemiluminescence portfolio.

Quantitative immunoassay for measuring kappa free light chains in human serum or plasma. Used for detecting and monitoring light chain disorders, multiple myeloma, and kidney disease. Compatible with automated chemiluminescence analyzers.

A multiplex assay for research use only (RUO) designed to quantitatively detect and measure neurofilament light chain (NfL) biomarker in human samples. The assay has a dynamic range of 1.25 pg/ml to 640 pg/ml with a limit of detection of 0.47 pg/ml. It can be used with plasma (recommended), serum, or cell culture supernatates for neurological disease research applications including Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.

A multiplex assay for research use only (RUO) designed to quantitatively detect and measure glial fibrillary acidic protein (GFAP) biomarker in human samples. The assay has a dynamic range of 3.125 pg/ml to 400 pg/ml with a limit of detection of 0.384 pg/ml. It can be used with serum (recommended), plasma, or cell culture supernatates for neurological disease research applications.

Quantitatively measures neurofilament light chain concentration in EDTA plasma on chemiluminescence analyzers. Aids in the assessment of neurological conditions and neurodegenerative diseases.

A multiplex assay for research use only (RUO) designed to quantitatively detect and measure two neurological biomarkers: glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in human samples. The assay can be used with serum (recommended), plasma, or cell culture supernatates for research applications in stroke, Alzheimer's disease, Parkinson's disease, and other neurological conditions. This product is not intended for traumatic brain injury (TBI) diagnostic use.

Innovative chemiluminescent assay products for routine and research applications in clinical diagnostics. Designed for specialized testing in endocrinology, diabetes diagnosis, and thyroid function assessment.